Vaxcyte advances with VAX-31 vaccine in late-stage trials, backed by strong cash and manufacturing setup.

Vaxcyte is transitioning from a single-product biotech to a commercial vaccine platform with its 31-valent pneumococcal conjugate vaccine, VAX-31, which offers broader serotype coverage than competitors. The vaccine is currently in pivotal Phase 3 trials for adults and Phase 2 trials for infants. Vaxcyte's strong financial position, including over $2.4 billion in cash and a completed manufacturing facility, supports simultaneous late-stage development and commercial readiness. Key upcoming milestones include the OPUS-1 Phase 3 trial results expected in Q4 2026 and additional adult and infant data in 2027, positioning Vaxcyte as a potential leader in next-generation vaccines.